Israel Englander’s Apogee Therapeutics APGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$198M Buy
1,491,404
+1,398,812
+1,511% +$126M 0.07% 244
2026
Q1
$7.79M Sell
92,592
-48,135
-34% -$3.5M ﹤0.01% 2430
2025
Q4
$10.6M Sell
140,727
-289,736
-67% -$18.2M ﹤0.01% 2202
2025
Q3
$17.1M Buy
430,463
+185,330
+76% +$7.08M 0.01% 1829
2025
Q2
$10.6M Sell
245,133
-15,202
-6% -$578K 0.01% 2191
2025
Q1
$9.73M Buy
260,335
+130,164
+100% +$5.03M 0.01% 2225
2024
Q4
$5.9M Buy
130,171
+40,162
+45% +$2.05M ﹤0.01% 2675
2024
Q3
$5.29M Sell
90,009
-7,056
-7% -$338K ﹤0.01% 2791
2024
Q2
$3.82M Sell
97,065
-21,909
-18% -$1.06M ﹤0.01% 2969
2024
Q1
$7.91M Buy
118,974
+90,199
+313% +$3.94M ﹤0.01% 2417
2023
Q4
$804K Buy
+28,775
New +$577K ﹤0.01% 4317

Other funds holding APGE

Israel Englander's APGE Position: Q2 2026 in Review

Israel Englander increased its Apogee Therapeutics (APGE) stake by 1,511% in Q2 2026, buying an estimated $126M and bringing the position to 1,491,404 shares worth $198M. The position accounts for 0.07% of the portfolio, ranked #244.

Israel Englander first reported a position in APGE in Q4 2023 and has held it in 11 quarters since. 285 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Israel Englander held 1,491,404 shares of Apogee Therapeutics worth $198M as of Q2 2026.
  • Israel Englander bought 1,398,812 Apogee Therapeutics shares in Q2 2026, an estimated $126M.
  • Apogee Therapeutics made up 0.07% of Israel Englander's portfolio in Q2 2026, its #244 holding.
  • Israel Englander first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 285 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.